ArticleAmerican journal of respiratory cell and molecular biology2026
MCT4 mediates hypoxia-induced extracellular lactate release from IPF fibroblasts.
Article in American journal of respiratory cell and molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The METTL3/LOXL2 axis participates in aberrant epithelial-fibroblast crosstalk and induces oral submucous fibrosis in rats.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Lactate is increased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and in mice with experimental lung fibrosis, and lactate has been linked to the pathogenesis of lung fibrosis. IPF fibroblasts in hypoxic conditions generate increased lactate due to an imbalance of lactate dehydrogenase isoforms that induce pyruvate conversion to lactate. Monocarboxylate transporter 4 (MCT4) functions as a key lactate export protein, but its role has not been studied in lung fibrosis. We hypothesized that MCT4 would have a critical role in the ability of IPF fibroblasts to generate extracellular lactate and found that MCT4 was significantly upregulated in IPF fibroblasts under hypoxic conditions. In contrast, the lactate importer protein, monocarboxylate transporter 1 (MCT1) did not significantly change in control or IPF fibroblasts. Pharmacologic inhibition and silencing of MCT4 reduced extracellular lactate generation by IPF fibroblasts. Supporting its role in lung fibrogenesis, MCT4 was increased in bleomycin-injured mice and in lungs from IPF patients. Importantly, normal fibroblasts incubated with conditioned media from IPF fibroblasts exposed to hypoxic conditions had increased α-smooth muscle actin expression that was attenuated by inhibition of MCT4 in the donor IPF fibroblasts or by inhibition of the lactate receptor GPR-81 in the recipient normal fibroblasts. Together, these findings implicate MCT4 in the ability of IPF fibroblasts to increase extracellular lactate and highlight the role of lactate signaling via G-protein coupled receptor-81 in normal fibroblast differentiation. We propose a novel paradigm in which lactate export, driven by increased MCT4 expression, promotes fibrosis in oxygen-deficient microenvironments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.